Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 11
Submit an article Journal homepage
309
Views
123
CrossRef citations to date
0
Altmetric
Drug Evaluation

Investigations on gossypol: past and present developments

Kalliopi Dodou Sunderland Pharmacy School, University of Sunderland, Wharncliffe Street, Sunderland SR1 3SD, UK. [email protected]
Pages 1419-1434 | Published online: 28 Oct 2005

Bibliography

  • KING TJ, DE SILVA LB: Optically active gossypol from Thespesia Populnea. Tet. Lett. (1968) 3:261–263.
  • JAROSZEWSKI JW,-HANSEN T, HANSEN SH, THASTRUP O, KOFOD H: On the botanical distribution of chiral forms of gossypol. Planta Med. (1992) 58:454–458.
  • STIPANOVIC R, STOESSL A, STOTHERS JB, ALTMAN DW, BELL AA, HEINSTEIN P: The stereochemistry of the biosynthetic precursor of gossypol. J. Chem. Soc. Chem. Commun. (1986):100–102.
  • ABOU-DONIA MB: Physiological effects and metabolism of gossypol. Residue Rev (1976) 61:125–160.
  • ••This article provides an extensive review ofthe properties of gossypol.
  • ADAMS R, MORRIS RC, TA, BUTTERBAUGH DJ, KIRKPATRICK EC: Structure of gossypol. An interpretation of its reaction.. Am. Chem. Soc. (1938) 60:2193–2203.
  • EDWARDS JD: Total synthesis of gossypol. J. Am. Chem. Soc. (1958) 80:3798–3799.
  • WU D: An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive and in gynaecological disease. Drugs (1989) 38(3):333–341.
  • COUTINHO EM: Gossypol: a for men. Contraception (2002) 65:259–263.
  • FREEDMAN TB, CAO X, OLIVIERA RV, CASS QB, NAFIE L: Determination of the absolute configuration and solution conformation of gossypol by vibrational dichroism.(2003)15:196–200.
  • JAROSZEWSKI JW,-HANSEN T, HANSEN LL: Optical stability of gossypol. Oniality (1992) 4:216–221.
  • BRZEZINSKI B, JERSZY O, PASZYC S, ARIPOV TF: 1H NMR studies of gossypol and its complexes with some organic compounds. Mol Struct. (1990) 220:261–268.
  • MARCINIAK B, SCHROEDER G, KOZUBEK H, BRZEZINSKI B: Spectroscopic and kinetic studies of the-lactol tautomerisation of gossypol solution. J. Chem. Soc. Perkin Trans.1991) 2:1359–1362.
  • PRZYBYLSKI P, WOJCIECHOWSKI G, BRZEZINSKI B, KOZUBEK H, MARCINIAK B, PASZYC S: Spectroscopic and semiempirical studies of gossypol complexes with Fe2-1 and Fe3+ cations. Struct. (2001) 569:147–155.
  • JAROSZEWSKI JW, KAPLAN O, COHEN JS: Action of gossypol and rhodamine 123 on wild type and multidrug-resistant MCF-7 human breast cancer cells: 31P nuclear magnetic resonance and toxicity studies. Cancer Res. (1990) 50:6936–6943.
  • OLIVER CL, BAUER JA, WOLTER KG et al.: LI vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin. Cancer Res. (2004) 10(22):7757–7763.
  • BAUER JA, TRASK DK, KUMAR B et al: Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bc1-Xl. Mol Cancer Ther. (2005) 4(7):1096–1104.
  • SHELLEY MD, HARTLEY L, GROUNDWATER PW et al: Structure-activity studies on gossypol in tumour cell lines. Anticancer Drugs (2000) 11(3):209–216.
  • BLACKSTAFFE L, SHELLEY MD, FISH RG: Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines. Melanoma Res. (1997) 7:364–372.
  • STEIN RC, JOSEPH AEA, MATLIN SA et al.: A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother. Pharmacol (1992) 30:480–482.
  • FLACK MR, PYLE RG, MULLEN NM et al.: Oral gossypol in the treatment of metastatic adrenal cancer. J. Metab. (1993) 76(01019–1024.
  • BUSHUNOW P, REIDENBERG MM, WASENKO J et al.: Gossypol treatment of recurrent adult malignant gliomas. Neurooncol (1999) 43:79–86.
  • VAN POZNAK C, SEDMAN AD, REIDENBERG MM et al.: Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a Phase I/II clinical trial. Breast Cancer Res. Treatment (2001) 66:239–248.
  • QIU J, LEVIN LR, BUCK J, MM: Different pathways cell killing by gossypol enantiomers. Exp. Biol. Med. (2002) 227(6):398–401.
  • RADLOFF RJ, DECK LM, ROYER RE, VANDER JAGT DL: Antiviral activities of gossypol and its derivatives against herpes simplex virus type II. Res. Commun. (1986) 18(10:1063–1073.
  • LIN TS, SCHINAZI R, GRIFFITH BP et al: Selective inhibition of human immunodeficiency virus type 1 by the () but not the (+) enantiomer of gossypol. Antimicrob. Agents Chemother. (1989) 3(12):2149–2151.
  • RAZAKANTOANINA V, PHUNG NKP JAUREGUIBERRY G: Antimalarial activity of new gossypol derivatives. Parasit. Res. (2000) 86:665–668.
  • VANDER JAGT DL, DECK LM, ROYER RE: Gossypol: prototype of inhibitors targeted to dinucleotide folds. Cur. Med. Chem. (2000) 7:479–498.
  • •This review on gossypol's biological activity focuses on its inhibitory effect on dehydrogenase enzymes.
  • GONZALEZ-GARZA MT, MATLIN SA, MATA-CARDENAS B, SAID-FERNANDEZ S: Differential effects of the (+) and (-)-gossypol enantiomers upon Entamoeba histolytica axenic cultures.. Pharmacol (1993) 45:144–145.
  • MONTAMAT EE, BURGOS C, DE BURGOS NM, ROVAI LE, BLANCO A, SEGURA EL: Inhibitory action of gossypol on enzymes and growth of Trypanosoma cruzi Science (1982) 218:288–289.
  • DODOU K, ANDERSON RJ, WJ, SMALL DAP, MD, GROUNDWATER PW: Synthesis of gossypol atropisomers and derivatives and evaluation of their antiproliferative and antioxidant activity. Bioorg. Med. Chem. (2005) 13(13):4228–4237.
  • ••This article provides detailed chemicalcharacterisation of gossypol derivatives, and in vitro studies for potential antipsoriatic activity.
  • JANERO DR, BURGHARDT B: Protection of rat myocardial phospholipid against peroxidative injury through superoxide- (xanthine oxidase)-dependent, iron-promoted Fenton chemistry by the male contraceptive gossypol.. Pharmacol (1988) 37(17):3335–3342.
  • LAUGHTON MJ, HALLIWELL B, EVANS PJ, HOULT JR: Antioxidant and prooxidant actions of the phenolics quercetin, gossypol, and myricetin. Biochem. Pharmacol (1989) 38(17):2859–2865.
  • LI ASH, BANDY B, TSANG SS, DAVISON AJ: DNA-breaking versus DNA-protecting activity of four phenolic compounds in vitro. Free Rad. Res. (2000) 33:551–566.
  • JOSEPH AEA, MATLIN SA, KNOX P: Cytotocity of enantiomers of gossypol. Br. J. Cancer (1986) 54:511–513.
  • LEE CYG, MOON YS, YUAN JH, CHEN AF: Enzyme inactivation and inhibition by gossypol. Mol Gel Biochem. (1982) 47:65–70.
  • UENO H, SAHNI MK, SEGAL SJ, KOIDE SS: Interaction of gossypol with sperm macromolecules and enzymes. Contraception (1988) 37(3):333–341.
  • BURGOS C, GEREZ DE BURGOS NM, ROVAI LE, BLANCO A: In vitro inhibition by gossypol of oxidoreductases from human tissues. Biochem. Pharmacol (1986) 35(5):801–804.
  • CONNERS R, SCHAMBACH F, READ J et al.: Mapping the binding site of gossypol-like inhibitors of Plasmodium fakiparum lactate dehydrogenase. Biochem. Parasitol (2005) 142:137–148.
  • YU Y, DECK A, HUNSAKER LA et al: Selective active site inhibitors of human lactate dehydrogenases A4, B4 and C4. Biochem. Pharmacol (2001) 62:81–89.
  • McCLARTY GA, CHAN AK, DC, WRIGHT JA: reductase: an intracellular target for the male antifertility agent, gossypol. Biochem. Biophys. Res. Commun. (1985) 133(1):300–305.
  • VAINIO P, THUREN T, WICHMAN K, LUUKKAINEN T, KINNUNEN PK: Hydrolysis of phospholipids monolayers by human spermatozoa. Inhibition by male contraceptive gossypol.. Biophys. Acta (1985) 814(2):405–408.
  • TENG CS: Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity. Contraception (1995) 52:389–395.
  • TUSZYNSKI GP, COSSU G: Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res. (1984) 44:768–771.
  • COYLE T, LEVANTE S, SHETLER M, WINFIELD J: LI vitro and in vivo cytotoxicity of gossypol against central nervous system tumour cell lines.. (1994) 19:25–35.
  • WANG YC, RAO PN: Effect of gossypol on DNA synthesis and cell cycle progression of mammalian cells in vitro. Cancer Res. (1984) 44:35–38.
  • TANG F, TSANG AYF, LEE C, PYD: Inhibition of catechol-0-methyl transferase by gossypol: the effect of plasma proteins. Contraception (1982) 26(5):515–519.
  • SMIT NPM, PAVEL S, KAMMEYER A, WESTERHOF W: Determination of catechol- 0-methyl transferase activity in relation to melanin metabolism using high performance liquid chromatography with fluorimetric detection1. Anal. Biochem. (1990) 190:286–291.
  • REKHA GK, SLADEK NE: Inhibition of human class 3 aldehyde dehydrogenase, and sensitisation of tumour cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol. In: Enzymology and Molecular Biology of Carbonyl Metabolism. Weiner H, DW, Flynn TG et al. (Eds), Plenum Press, New York, USA (1996) 6:133–146.
  • MESSIHA FS: Effect of gossypol on kinetics of mouse liver alcohol and aldehyde dehydrogenase. Gen. Pharmacol (1991) 22(4):573–576.
  • BENZ CC, KENIRY MA, FORD JM et al: Biochemical correlates of the antitumour and antimitochondrial properties of gossypol enantiomers. Mol Pharmacol (1990) 37:840–847.
  • FORD JM, HAIT WN, MATLIN SA, BENZ CC: Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers. Cancer Lett. (1991) 56:85–94.
  • JARVIS WD, TURNER AJ, POVIRK LF, TRAYLOR RS, GRANT S: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukaemia cells by pharmacological inhibitors of protein kinase C. Cancer Res. (1994) 54(7):1707–1714.
  • ROSENBERG LJ, ADLAKHA RC, DESAI DM, RAO PN: Inhibition of DNA polymerase a by gossypol.. Biophys. Acta (1986) 866:258–267.
  • KABLE EP, PARSONS PG: Potency, selectivity and cell cycle dependence of catechols in human tumour cells in vitro. Biochem. Pharmacol (1988) 37(9):1711–1715.
  • MEGO M: Telomerase inhibitors in anticancer therapy: gossypol as a potential telomerase inhibitor. Broth]. Lek. Listy (2002) 103(10):378–381.
  • HIIPAKKA RA, ZHANG HZ, DAI W, DAI Q, LIAO S: Structure-activity relationships for inhibition of human 5a-reductases by polyphenols.. Pharmacol (2002) 63:1165–1176.
  • TRIPATHI AK, DESAI PV, PRADHAN A et al.: An a-proteobacterial type malate dehydrogenase may complement LDH function in Plasmodium fakiparum. Eur. Biochem. (2004) 271:3488–3502.
  • DANDO C, SCHROEDER ER, HUNSAKER LA et al.: The kinetic properties and sensitivities to inhibitors of lactate dehydrogenases (LDH1 and LDH2) from Toxoplasma gondii: comparisons with pLDH from Plasmodium fakiparum. Mol Biochem. Parasitol (2001) 118(1):23–32.
  • GEREZ DE BURGOS NM, BURGOS C, MONTAMAT EE, ROVAI LE, BLANCO A: Inhibition by gossypol of oxidoreductases from Trypanosoma cruzi. Pharmacol (1984) 33(7):955–959.
  • LIN TS, SCHINAZI RF, ZHU J et al: Anti-HIV-1 activity and cellular pharmacology of various analogs of gossypol. Biochem. Pharmacol (1993) 46(2):251–255.
  • KELLER PA, BIRCH C, LEACH SP, TYSSEN D, GRIFFITH R: Novel pharmacophore-based methods reveal gossypol as a reverse transcriptase inhibitor. Graphics Model. (2003) 21:365–373.
  • REIDENBERG MM: Environmental inhibition of 1 10-hydroxysteroid dehydrogenase. Toxicology (2000) 144:107–111.
  • SONG D, LORENZO B, MM: Inhibition of 11 13-hydroxysteroid dehydrogenase by gossypol and bioflavonoids. J. Lab. Clin. Med. (1992) 120(5):792–797.
  • SANG GW, LORENZO B, MM: Inhibitory effects of gossypol on corticosteroid 11-3- dehydrogenase from guinea pig kidney: a possible mechanism for causing hypokalaemia. J. Steroid Biochem. Molec. Biol. (1991) 39(2):169–176.
  • MOH PP, LI PK, DARBY MV, BRUEGGEMEIER RW, LIN YC: Characteristics of covalent gossypol binding to microsomal proteins. Res. Commun. Chem. Path. Pharmacol. (1992) 76(3):305–322.
  • YU YW: Probing into the mechanism of action, metabolism and toxicity of gossypol by studying its (+) and 0 stereoisomers. Ethnopharmacol. (1987) 20:65–78.
  • DECK LM, CHAMBLEE BB, RE, HUNSAKER LA, JAGT DL: Inhibition of aldose reductase by gossypol and gossypol-related compounds. In: Enzymology and molecular biology of carbonyl metabolism. Weiner H (Ed.), Kluwer Academic/Plenum Publishers, New York, USA (1999) 7:487–491.
  • KAWANISHI K, UEDA H, MORIYASU: Aldose reductase inhibitors from the nature. Curr. Med. Chem. (2003) 10(15):1353–1374.
  • YU BZ, ROGERS J, RANADIVE G et al.: Gossypol modification of Ala-1 of secreted phospholipase A2: a probe for the kinetic effects of sulfate glycoconjugates. Biochemistry (1997) 36:12400–12411.
  • JAN CR, LIN MC, CHOU KJ, HUANG JK: Novel effects of gossypol, a chemical contraceptive in man: mobilisation of internal Ca2' and activation of external Ca2' entry in intact cells. Biochim Biophys. Acta (2000) 1496:270–276.
  • FORSTER S, ILDERTON E, NORRIS JFB, SUMMERLY R, YARDLEY HJ: Characterisation and activity of phospholipase A2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema. Br. .1. Dermatol. (1985) 112:135–147.
  • BAUMGRASS R, WEIWAD M, ERDMANN F et al.: Reversible inhibition of calcineurin by the polyphenolic aldehyde gossypol. J. Biol. Chem. (2001) 276(51):47914–47921.
  • PHYLLIS JW, DIAZ FG, OREGAN MH, PILITSIS JG: Effects of immunosuppressants, calcineurin inhibition, and blockade of endoplasmic reticulum calcium channels on free fatty acid efflux from the ischaemic/reperfused cerebral cortex. Brain Res. (2002) 957(1):12–24.
  • OLGIATI KL, TOSCANO DG, WM, TOSCANO WA: Gossypol inhibition of adenylate cyclase. Arch. Biochem. Biophys. (1984) 231(2):411–415.
  • LIU S, KULP SK, SUGIMOTO Y et al.: The 0-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anti-Cancer Res. (2002) 22:33–38.
  • LIGUEROS M, JEOUNG D, TANG B, HO CHHAUSER D, REIDENBERG MM, SONENBERG M: Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected fibrosarcoma cells. Br. I Cancer (1997) 76(1):21–28.
  • JIANG J, SUGIMOTO Y, LIU S et al.: The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor 131 (TGF131) signal transduction pathway. Anti-Cancer Res. (2004) 24(1):91–100.
  • •This research article presents the current findings on the mechanism of the antineoplastic effect of gossypol on prostate cancer cells.
  • ZHANG M, LIU H, GUO R et al.: Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem. Pharmacol (2003) 66:93–103.
  • KITADA S, LEONE M, SARETH S, ZHAI D, REED JC, PELLECCHIA M: Discovery, characterisation, and structure-activity relationships studies of proapoptotic polyphenols targetting B-cell lymphocyte/ leukaemia-2 proteins.' Med. Chem. (2003) 46(20):4259–4264.
  • OLIVER CL, MIRANDA MB, SHANGARY, LAND S, WANG S, JOHNSON DE: 0-Gossypol acts on the mitochondria to overcome Bc1-2and Bcl-XL-mediated apoptosis resistance. Mol. Cancer Ther. (2005) 4(1):23–31
  • MOHAMMAD RM, WANG S, A et al.: Preclinical studies of a nonpeptidic small-molecule inhibitor of Bc1-2 and Bc1-X(L) [(-)-gossypol] against diffuse large cell lymphoma.. Cancer Ther. (2005) 4(1):13–21.
  • •This article presents recent research on a potentially successful therapeutic use of gossypol in diffuse large cell lymphoma.
  • XU L, YANG D, WANG S et al.: 0- enhances response to radiation and results in tumour regression of human prostate cancer. Mol. Cancer Ther. (2005) 4(2):197–205.
  • •This article presents recent research on a potentially successful therapeutic use of gossypol on human prostate cancer.
  • HOU DX, UTO T, TONG X et al.: Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. Arch. Biochem. Biophys. (2004) 428:179–187.
  • CHANG JS, HSU YL, KUO PL, CHIANG LC, LIN CC: Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalised human alveolar lung cancer cell line. Clin. Exp.. Physic] (2004) 31(10):716–722.
  • •This research article presents current findings on the mechanism of the antineoplastic effect of gossypol on lung cancer cells.
  • KOCAK M, BOZDOGAN O, ERKEK E, ATASOY P, BIROL A: Examination of Bc1-2, Bcl-X and box protein expression in psoriasis. Int. J. Dermatol (2003) 42(10):789–793.
  • TAKAHASHI H, MANABE A, ISHIDA-YAMAMOTO A, HASHIMOTO Y, IIZUKA H: Aberrant expression of apoptosis-related molecules in psoriatic epidermis. I Dermot. Science (2002) 28:187–197.
  • FUKUYA Y, HIGAKI M, HIGAKI Y, KAWASHIMA M: Effect of vitamin D3 on the increased expression of Bc1-xL in psoriasis. Arch. Dermatol. Res. (2002) 293(12):620–625.
  • CUELLAR A, RAMIREZ J: Further studies on the mechanism of action of gossypol on mitochondrial membrane. Int. J. Biochem. (1993) 25(8):1149–1155.
  • DE PEYSTER A, HYSLOP PA, KUHN CE, SAUERHEBER RD: Membrane structural/functional perturbations induced by gossypol. Effects on membrane order, liposome permeability, and insulin-sensitive hexose transport. Biochem. Pharmacol. (1986) 35(19):2193–3300.
  • TANPHAICHITR N, NAMKING M, TUPPER S, HANSEN C, WONG PTT: Gossypol effects on the structure and dynamics of phospholipid bilayers: a FT-IR study. Chem. Phys. Lipids (1995) 75:119–125.
  • SHELLEY MD, HARTLEY L, FISH RG et al.: Stereospecific cytotoxic effects of gossypol enantiomers and gossypolone in cell lines. Cancer Lett. (1999) 135:171–180.
  • GILBERT NE, O'REILLY JE, CJG, LIN YC, RW: Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Lai. Sci. (1995) 57(1):61–67.
  • MENG X, RIORDAN NH, HD et al: Cell membrane fatty acid composition differs between normal and malignant cell lines. RE. Health Li. (2004) 23(2):103–106.
  • ZHUANG L, KIM J, ADAM RM, SOLOMON KR, FREEMAN MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts." Chu. Invest. (2005) 115(4):959–968.
  • HERVE JC, BASTIDE FP, CRONIER L et al.: Contraceptive gossypol blocks cell-to-cell communication in human and rat cells. Eur. Pharmacol (1996) 313:243–255.
  • KUHN G, CERMAK R, MINCK K, VUJICIC Z, SCHARRER E: Gossypol induces chloride secretion in rat proximal colon. Eur. Pharmacol (2002) 457:187–194.
  • HUTCHINSON RW, BARHOUMI R, MILES JM, BURGHARDT RC: Attenuation of gossypol cytotoxicity by cyclic AMP in rat liver cell line. Toxicol Appl. Pharmacol (1998) 151(2):311–318.
  • HU F, MAH K, TERAMURA DJ: Gossypol effects on cultured normal and melanocytes. hi vitro Gel Dev. Biol. (1986) 22(10):583–588.
  • CUELLAR A, DIAZ-SANCHEZ V, RAMIREZ J: Cholesterol side-chain cleavage and 11 0-hydroxylation are inhibited by gossypol in adrenal cortex mitochondria. I Steroid Biochem. Mol (1990) 37(4):581–585.
  • ABOU-DONIA MB, DIECKERT JW: Gossypol: uncoupling of the respiratory chain and oxidative phosphorylation. Life Li. (1974) 14:1955–1963.
  • REYES J, WYRICK SD, BORRIERO L, BENOS DJ: Membrane actions of male contraceptive gossypol tautomers.. Biophys. Acta (1986) 863:101–109.
  • HAAS RH, SHIRLEY DA: The oxidation of gossypol. Formation of gossypolone with ferric chloride. Org. Chem. (1965) 30:4111–4113.
  • DAO VT, DOWD MK, GASPARD C et al: New thioderivatives of gossypol and gossypolone, as prodrugs of cytotoxic agents. Bioorg. Med. Chem. (2003) 11:2001–2006.
  • DAO VT, GASPARD C, MAYER M, WERNER GH, NGUYEN SN, MICHELOT RJ: Synthesis and cytotoxicity of gossypol related compounds. Eur. Med. Chem. (2000) 35:805–813.
  • MILLER RF, ADAMS R: Structure of gossypol. Anhydrogossypol and its derivatives. J. Am. Chem. Soc. (1937) 59:1736–1738.
  • BAND V, HOFFER AP, BAND H et al: Antiproliferative effect of gossypol and its isomers on human reproductive cancer cell lines. Cynecol Oncol (1989) 32:273–277.
  • LEBLANC M, RUSSO J, KUDELKA A, SMITH JA: An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. Pharmacol Res. (2002) 46(6):551–555.
  • IKEDA M: Inhibition kinetics of NAD-linked enzymes by gossypol acetic acid. Andrologia (1990) 22:409–416.
  • WONG RC, NAKAGAWA Y, GE: Studies on the nature of the inhibition by gossypol of the transformation of pepsinogen to pepsin. J. Biol. Chem. (1972) 247(5):1625–1631.

Websites

  • http://www.malvaceae.info/Genera/ Gossypium/gallery.html gallery.
  • http://www.malvaceae.info/Genera/ Thespesia/gallery.html gallery

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.